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Rabies viruses isolated from different animal species in various parts of the world 
were  in  the  past  considered  to  be  antigenically  closely  related.  Only  when  the 
antibodies produced in animals immunized with whole virions or viral components 
were assayed by the plaque reduction method, were some minor differences detected 
in  the  antigenic  composition  of  various  rabies  strains  (1).  On  the  other  hand, 
monoclonal  antibodies,  produced  by  the  hybrids  of  mouse  myeloma  cells  with 
splenoeytes of rabies-immunized BALB/c mice and directed against either nucleocap- 
sid or glycoprotein of the virus, provided categorical evidence of antigenic differences 
among several fixed and street rabies viruses (2). 
The notion of antigenic differences among rabies virus strains may be of particular 
importance in rabies prophylaxis. Most vaccines used in humans for protection after 
exposure are derived  from a  rabies virus originally  isolated  and  adapted  to rabbit 
brain  by Pasteur  in  1882  (3).  It was  assumed  that  this  strain  had  sufficient  cross- 
reactivity with all field strains of rabies virus in different geographical areas to protect 
exposed individuals. 
Unfortunately, the postexposure treatment of rabies is not  100% effective. Failure 
to protect exposed individuals has been attributed either to low potency of the vaccine 
or to a delay in beginning treatment. Occasionally, however, failure occurs even when 
the vaccine can be assumed to be potent and the treatment prompt (4, 5). Antigenic 
differences among strains of rabies virus were suspected to be responsible, but until 
now, there was no way to detect these differences. 
The  purpose  of the  studies  presented  in  this  paper  was:  (a)  either  to  produce 
variants of rabies virus in the laboratory or to select variants from naturally occurring 
(street)  viruses,  (b)  to  study  antigenic  specificities  of these  variants  by  means  of 
monoclonal antibodies, and (c) to undertake cross-protection tests in mice immunized 
with either standard rabies vaccines or vaccines produced by variants and challenged 
with homologous and variant viruses. 
Materials and Methods 
Hybridoma Monoclonal Antibodies.  Hybridomas, which secrete monoclonal antibodies specific 
for rabies virus nucleoproteins, glycoproteins,  and two membrane proteins, were produced by 
the fusion  of P3  ×  63 Ag8 cells with splenocytes  of BALB/c mice immunized with several 
strains of rabies virus  (2,  6).  Mice  were  inoculated  twice  at  4-  to  8-wk  intervals  with  an 
inactivated virus suspension.  3-4 d after the second injection,  mouse splenocytes were fused 
with mouse myeloma cells and incubated  in selective  hypoxanthine-aminopterin-thymidine 
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(HAT) ~ medium. The selection and cloning of hybridomas produced by the fusion of the two 
types of cells have been described elsewhere (2).  In the present investigation, 21  hybridomas 
specific for nucleocapsid (7) and 24 hybridomas specific for glycoprotein (8) of rabies virus were 
used. 
Viruses 
LABORATORY STRAINS.  CVS-II, the challenge standard virus (CVS)  (9) was propagated in 
baby hamster kidney (BHK-21) cells as previously described (10).  A  virus pool representing 
second passage after two serial clonings had an infectivity titer of 6 X  107 plaque-forming units 
(PFU)/ml;  CVS-DEV, the vaccine strain (I 1), received from Eli Lilly and Co., Indianapolis, 
Ind., was propagated for three passages in BHK-21  cells; PV-II, the vaccine strain, received 
from Bureau of Biologics, Bethedsa, Md., was propagated for 58 passages in human diploid cell 
cultures (12). 
FIELD ISOLATES  OF HUMAN ORIGIN.  Eight coded rabies virus field isolates were provided by 
Dr. G. M.  Baer, Center for Disease Control  (CDC), Atlanta, Ga. The original material was 
homogenized and clarified by centrifugation. The supernatant fluid was injected intracerebraily 
into groups of 5-wk-old ICR mice. When paralyzed, animals were sacrificed, and their brains 
were harvested for use in nucleocapsid antigen analysis as previously described (6),  and  for 
challenge experiments (see below). 
BHK-21 cells in culture were infected with the clarified original brain suspensions, and virus 
was propagated in those cells for two or three additional passages. When the tissue culture 
fluids from infected cells contained at least 1,000 infective units of virus/ml, they were used in 
the neutralization assay. 
Virus Neutralization.  The  susceptibility of CVS-11,  CVS-11-derived  variants,  and  street 
rabies viruses to neutralization by different hybridoma antibodies was evaluated by determining 
the virus neutralization index (7).  Briefly, serial dilutions of virus were mixed with constant 
amounts of hybridoma medium and incubated at  37°C  for  1 h.  In the case of CVS-11  and 
CVS-11  variants, the remaining infectivity was determined by infecting CER  hamster cells' 
monolayers (13) and counting plaques produced after 4 d of incubation under nutrient agarose 
overlay. In the case of street viruses, the remaining infectivity was determined by infection of 
BHK-21 cells and staining foci of infected cells by fluorescent antibody (FA) staining technique. 
The neutralization index was determined by substracting either the number of plaques or FA- 
foci/ml in cultures infected with virus and antibody mixtures, from the number of plaques or 
FA-foci/ml in mixtures of virus and normal medium. 
Titration of Neutralizing Antibody in Serum of Immunized Mice.  The level of virus-neutralizing 
antibody in immunized mice was determined by the rapid fluorescent focus-inhibition technique 
that has been described elsewhere (13). 
Immunofluorescent Antibody Staining  for Nucleocapsid  Antigen.  The reactivity of anti-nucleocapsid 
monoclonal antibodies with antigen present in brains of rabies virus-infected mice was detected 
by the indirect FA staining procedure as previously described (6). 
Selection of Variants.  Serial  10-fold dilutions of virus were prepared and mixed with equal 
volumes of Eagle's minimal essential medium (MEM) or hybridoma antibody diluted in MEM. 
After  1 h  of incubation at  37°C,  0.1  ml of virus antibody mixture was added to CER  cell 
monolayers (14) grown in 60-ram Petri dishes. After adsorption for I h, 5 ml of nutrient agarose, 
with or without hybridoma antibody, was poured over the cell layers. Plates were incubated at 
35°C  for 4  d  and were scored for the presence of rabies virus-induced plaques, which were 
visible without  staining.  At  the  end  point  of neutralization,  well  separated  plaques  were 
collected with  a  Pasteur  pipette and  dispersed  in  5  ml  MEM  containing  1 ×  l0  s  freshly 
trypsinized BHK-21 cells in T-25 Falcon plastic tissue culture flasks (Falcon Labware, Div. of 
Becton, Dickinson, & Co., Oxnard, Calif.). Portions of 0.5 ml infected cells were transferred 
into  wells  of four-chamber  Lab-Tek  tissue  culture  slides  (Lab-Tek  Products,  Div.  Miles 
Laboratories, Inc., Naperville, Ill.). The T-25 flasks and Lab-Tek slides were incubated for 3 d. 
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The presence of virus in the culture was detected by FA staining. 
Several clones of virus obtained by this technique from each neutralization test were assayed 
for resistance to neutralization by the hybridoma antibody used for their selection. 
Unless otherwise stated,  1:5 dilution of hybridoma antibody was used to select variants and 
to test resistance to neutralization. 
Vaccine.  Concentrated,  ~-propiolactone-inactivated  vaccine  was  prepared  as  previously 
described (15) from BHK-21 cells infected with two fixed viruses, CVS-11 and PV-11, and with 
selected variant strains. 
Immunization and Challenge.  6-wk-old ICR  mice were injected intraperitoneally with 0.5  ml 
of a  1:50 dilution of vaccine twice weekly.  Animals were challenged 7 d  after the last dose of 
vaccine by intracerebrai inoculation with serial  10-fold dilutions of homologous and heterolo- 
gous viruses. The infectivity titers of challenge virus were determined by intracerebral inocula- 
tion into unvaccinated control mice. Animals were examined daily for 3 wk for signs of rabies. 
Some animals were sacrificed when in extremis, and the presence of rabies virus was confirmed 
by FA staining of brain tissue impressions and by reisolation of virus in BHK-21  cell cultures, 
or by intracerebral inoculation into mice. 
Results 
Selection of Variants.  An  example of selection of a  variant  virus by exposing the 
parental CVS to an overneutralizing amount ofmonoclonal antiglycoprotein antibody 
is shown in Table I. It can be seen that in cultures containing hybridoma antibody 
101-1 diluted 1:20, the infectivity titer of the CVS decreased from 107.7 to 10  a'7 PFU/ 
ml.  The same  antibody  diluted  1:100  decreased  the  titer  to  105.2 PFU/ml.  Virus 
grown  from  21  individual  plaques  obtained  in  the  presence of a  1:20  dilution  of 
hybridoma antibody 101-1 was resistant to neutralization by the selecting antibody. 
In contrast, the progeny of 16 plaques obtained in the presence of a  1:100 dilution of 
101-1  antibody remained  susceptible  to neutralization by the selecting hybridoma 
antibody.  Additional  groups  of variant  viruses were selected by exposing CVS  to 
seven different monoclonal antibodies. As shown in Table II, variants not neutralized 
by the  selecting antibody were consistently obtained  in  experiments in  which  the 
neutralization  index  (the  ratio of the  titer of CVS  in  the  presence of hybridoma 
antibodies to the CVS titer in the absence of antibody) was  104 or higher.  Using a 
variety of hybridoma antibodies,  the observed  frequency of variants  in  individual 
glycoprotein epitopes was between 10  -4.3 and  10  -4.9 per infectious unit of CVS. 
Antigenic Analysis of Variant Viruses.  Five variant viruses, selected by titration of the 
cloned  parental  CVS-I1  strain  in  the  presence of an  overneutralizing amount  of 
TAnLE  I 
Selection of Variants of CVS Virus m the Presence  of Hybridoma Antibody 101-1 
Virus treatment 
PFU/plate at virus dilution (log  10) 
--1  --2  -3  -4  -5 
Infectiv- 
ity titer 
--6  (log 10) 
PFU/ml 
None  C  C  C  >100  45  5  7.7 
HAb 1:20  42 (16/16)*  5 (5/5)  0  0  0  0  3.7 
HAb 1:100  C  >100  16 (0/16)  0  0  0  5.2 
Dilutions of CVS were mixed with either 1:20 or 1:100 dilution of 101-1 hybridoma antibody (HAb) and 
added to CER monolayers; individual plaques were collected 4 d later. C, confluent. 
* 42, number of plaques observed; (16/16), number of virus clones not neutralized by hybridoma antibody 
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hybridoma  antibodies  101-1,  220-8,  231-22,  240-3,  and  226-11,  were  tested  in  a 
neutralization test against nine hybridoma antibodies. 
The following points are evident from Table III. First, the five CVS variants can 
readily be differentiated from each other by means of the hybridoma antibody panel. 
For instance,  HAb  101-1  neutralizes  all variant  viruses except  RV-101-1  and  thus 
demonstrates the uniqueness of RV-101-1.  Similarly, RV  220-8 and  RV  231-22 can 
be differentiated from all the variants and from each other by the HAb's 231-22 and 
162-5,  respectively. The  same holds here  for  variants  RV  240-3  and  RV  226-11  as 
evidenced, for instance, by HAb 226-11  and 613-2. Second, the variants seem to form 
two distinct groups: the variant group comprising RV  101-1, RV 220-8, and RV 231- 
22  exhibit changes  that  prevented several of the  top  four antibodies  (101-1,  220-8, 
162-5,  231-22)  from  neutralizing  the  variants  but  did  not  reduce  detectably  the 
neutralizing potency of five other antibodies (240-3  through  194-2).  In contrast,  the 
changes exhibited by the variant group RV  240-3 and RV 226-11  did not affect the 
neutralizing potency of the top four antibodies but abolished or reduced the neutral- 
izing potency of the bottom five antibodies of the hybridoma panel. The latter finding 
suggests that  the changes in the first and second variant  group  occurred in distinct 
antigenic sites of the viral glycoprotein which seem to vary independently from each 
other.  These sites will be referred to in the following as I  (modified on  variant  RV 
101-1, RV 220-8, and RV 231-22)  and II (RV 240-3 and RV 226-11). 
Additional support  for the notion of the independence of glycoprotein sites I  and 
II comes  from  the  demonstration  (Table IV)  that  no  variants were  observed when 
CVS  virus was  titrated in  the simultaneous  presence of two  hybridoma antibodies, 
one  (101-1)  directed against  site I  and  the other  (240-3)  against  site  II. Given  the 
frequency  of variants  (10  -4'1  and  10 -4"2)  in  the  epitopes  delineated  by  the  above 
TABLE  II 
Frequency of CVS Variants 
HAb used for se-  Neutralization  Variants per  Frequency of var- 
plaques  iants~  lection of variants  index (log 10)  analyzed* 
101-I  4.3  21/21  10  -4.3 
3.5  0/14  ND§ 
220-8  4.5  3/3  10  -4"s 
226-11  4.5  3/9  10  -5"° 
231-22  4.2  4/5  10  -4"a 
240-3  4.5  1/1  10  -4.3 
162-5  4.3  2/2  10  -4.3 
194-2  4.0  3/8  10  -4.4 
613-2  3.3  0/2  ND 
Dilutions of CVS were mixed with  1:5 dilution of the respective hybridoma 
antibody (HAb) except in case of 101-1 when  1:100 dilution was also used, 
and the mixture  was added to CER  monolayer.  From  plates  where well 
separated plaques were observed, virus clones were grown out and tested for 
neutralization  by HAb used for their selection. Neutralization  index was 
determined  by dividing number of PFU/ml of virus mixed with  normal 
medium over number of PFU/ml of virus mixed with antibody. 
* Number of virus clones not neutralized  by the HAb used for their selection 
to total number of virus clones isolated. 
:~ Number of variants per infectious unit of CVS. 
§ ND, not determined. T. J.  WIKTOR AND  H.  KOPROWSKI 
TABLE III 
Neutralization of CVS Standard and CVS Variants by Different Hybridoma Antibodies 
103 
Neutralization index of hybridoma antibodies reacting with parental 
virus and virus variants (log 10)  Hybridoma 
clone  Parent  RV 101-1  RV 220-8  RV 231-22  RV 240-3  RV 226-11  CVS- 11 
101-1  4.2  0  4.0  4.0  >4.0  >4.0 
220-8  4.3  0  0  0  >4.0  >4.0 
162-5  4.3  0  0  3.3  >4.0  >4.0 
231-22  4.3  4.5  0  0  >4.0  >4.0 
240-3  4.0  4.5  4.0  4.0  0  0 
226-11  >4.0  >4.0  >4.0  >4.0  0  0 
613-2  3.3  >3.0  >3.0  >3.0  >3.0  0 
194-2  4.2  4.5  >4.0  4.0  >4.0  3.0 
248-2  4.0  >4.0  >4.0  >4.0  >4.0  4.0 
Dilutions of CVS and variant strains mixed with  1:5 dilution of hybridoma medium were 
used to infect CER cells. 
TABLE  IV 
Attempts at Selecting a CVS Variant after Exposure to a Mixture of Two 
Hybridoma Antibodies 
Hybridoma antibody  Neutralization index (log 10) 
None  0 
101-1  4.1 
240-3  4.2 
101-1 and 240-3  >7.4 
Dilutions of CVS were mixed with 1:5 dilution of hybridoma antibody  101-1 
and 240-3, respectively, and with equal mixtures of the two hybridomas before 
infecting CER monolayers. 
antibodies,  the  expected  frequency  of variants  in  both  epitopes  should  equal  the 
product  of the  individual  variant  frequencies  (10  -s'a)  if the  two  epitopes  change 
independently from each other. Although the expected frequency of double variants 
was one log below the level of the detectability of the above experiment,  the failure 
to observe a  double variant  among  10  TM infectious units of CVS is compatible with 
the independent mutability of the glycoprotein sites I and II. 
Analysis  of  Variants  in  Protection  Experiments  In  Vivo.  The  results  shown  in  Fig.  1 
indicate  that  the  mice  immunized  with  CVS-11  vaccine  were  protected  against 
challenge with CVS-11 virus and against challenge with the variants RV 231-22 (site 
I)  and  RV  240-3  (site  II). In contrast,  mice immunized  with  variant  vaccines were 
protected only when challenged with the homologous variant; they remained suscep- 
tible, however, to challenge with either CVS- 11  virus or variants of the heterologous 
site.  Although the mortality  ratio  of mice vaccinated with  variants  and  challenged 
with  the parental  virus or variants  was,  at  some dilutions  of challenge  virus,  lower 
than  in  unvaccinated  control  mice,  inoculation  with  dilutions  10-1-10  -3  of  the 
challenge virus often caused the death of all  vaccinated  mice (Figs.  1 and  2).  Thus, 
vaccination  of mice with  RV  240-3  (site  II)  did  not  result  in  sufficient  protection 
against challenge with CVS-11 or RV 231-22 (site I) (Fig.  1). Conversely, vaccination 
with  RV 231-22 or RV  101-1  (both site  I)  produced  insufficient  protection  against 104  ANTIGENIC VARIANTS OF RABIES VIRUS 
challenge with CVS-11 or a  variant in the site II but protected well against variants 
in the I site (Figs.  1 and 2). 
To investigate whether the different degree of cross-protection observed in vivo was 
related to differences in the humoral immune response elicited by CVS- 11 and variant 
vaccine strains, the sera obtained from vaccinated mice before challenge were tested 
for their neutralizing potency against  the viruses used  for subsequent  challenge in 
vivo. The results shown in Table V clearly demonstrate that the prechallenge sera are 
not able to differentiate clearly between homologous and heterologous viruses. 
Variants of Street Rabies Virus.  We have described elsewhere (6) the great diversity 
in antigenic specificities of field strains of rabies virus which could be demonstrated 
by  means  of a  panel  of either  antinucleocapsid  or  antiglycoprotein  monoclonal 
antibodies.  Because mutant  virus vaccines failed to protect mice against  challenge 
with parental virus and other mutants, it became imperative to investigate whether 
vaccination with standard fixed virus vaccine protected against challenge with street 
viruses isolated directly from humans  who had  died of rabies, some of whom  had 
received the complete course of postexposure vaccinations. 
Before undertaking  the  protection  test,  it  was  necessary to  obtain  an  adequate 
number of samples  of street  virus  of human  origin  and  to  perform, by  means  of 
monoclonal antibodies, a  comparative antigenic analysis between field strains  and 
fixed viruses used  for vaccine production.  Eight  coded samples  of human-derived 
virus isolates were processed as described in Materials and Methods. Brain impressions 
from mice that had died after infection with the original material were examined by 
FA initially with a  panel of three hybridoma antibodies  (Table VI)  to rule out the 
possibility that not all of the isolates were rabies virus. In the test we have included 
in addition to the eight samples of street viruses, impression smears of mouse brains 
infected with two strains of fixed virus, PV- 11 and CVS-DEV (Table VI) used for the 
production of vaccines employed for immunization of man in this and other countries. 
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FIG. 2.  Protection by one variant vaccine against challenge with parental virus, by homologous 
virus, and by another variant of the same epitope. Percent mortality after challenge with indicated 
virus dilution. O, vaccinated mice; O, unvaccinated  controls. 
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T^BLE  V 
Cross-Neutralization between Parent CVS-I 1 and Variant Strains Derived 
from CVS-I I by Polyclonal Antibodies 
Serum from 
mice immunized 
with 
Virus neutralizing antibody titers against virus strains 
CVS-I 1  RV 231-22  RV 101-1  RV 240-3 
CVS- 11  2,400  800  800  800 
231-22  800  800  800  800 
101 - 1  2,400  2,400  6,000  2,400 
240-3  2,400  2,400  2,400  2,400 
Dilutions of sera from vaccinated mice obtained at the time of challenge (see 
text) were mixed with 100 ID6o  ofCVS-I 1 and variant strains and the mixture 
added to BHK-21 monolayer. Final dilution of antibody reducing the number 
of fluorescent foci by 50% was considered as end-point titration. 
As shown in Table VI all viruses (representing eight human isolates and two fixed 
viruses) react with antibodies 502-2 and  103-7, and none reacts with antibody 422-5. 
Antibody 502-2 has been shown  previously (6) to react with all strains of rabies and 
rabies-related viruses,  antibody  103-7  with  rabies viruses only, and  antibody 422-5 
with rabies-related viruses but not with rabies viruses. Thus, the results of the present 
assay indicate that  all the human  isolates were indeed rabies viruses.  Results of the 
second  part of the test  permitted  us  to subdivide the street  virus strains  into  three 
groups (1, 4, 5, 7, 8; 2, 6; 3) on the basis of antigenic properties of their nucleocapsids. 
In addition to the results shown in Table VI,  12 other antinucleocapsid hybridomas 
used in the FA test gave positive reactions with all the street and fixed viruses. 
More striking differences between the eight street strains and the two fixed viruses 
were observed in the neutralization test with a panel of 14 antiglycoprotein hybridoma 
antibodies. As shown in Table VII, antigenic analysis of the street virus isolates and 106  ANTIGENIC VARIANTS OF RABIES  VIRUS 
TABLE VI 
Analysis of Human Rabies Virus Isolates and Vaccine Strains with Anti- 
Nucleocapsid Monoclonal Antibodies 
Hybridoma 
clone 
Results of FA staining of human 
rabies virus isolates numbers 
Results of FA stain- 
ing of vaccine strains 
1, 4, 5, 7,  2 and 6  3  PV- 11  CVS- 
8  DEV 
502-2*  +  +  +  +  + 
103-7"  +  +  +  +  + 
422-5*  0  0  0  0  0 
377-3  +  +  +  +  0 
120-2  +  +  0  +  + 
237-3  0  +  +  +  + 
102-27  0  +  +  +  + 
364-11  0  +  +  +  + 
390  0  +  +  +  + 
An additional 12 antibodies reacted positively with all virus strains tested. 
Smears of brain cells of mice  dying after intracerebral  inoculation  with 
respective virus strains were stained by anti-mouse fluorescein conjugate after 
incubation  with hybridoma antibodies. +, positive fluorescence. 0, no fluo- 
rescence. 
* Used for identification of isolates or rabies viruses. 
of the  two  fixed  viruses  allows  identification  of six  patterns  of  reactivity  of  the 
hybridoma antibodies with  glycoprotein antigens expressed by the eight samples of 
street virus on the one hand and  the fixed viruses on  the other hand.  These results 
further permitted grouping street virus isolates 4, 5, and  7 into one group  (A),  1 and 
8  into another group  (B), 2 and 6  into the third group (C), and 3 alone representing 
the fourth group  (D). It is evident also that each of these street virus groups differed 
antigenically from either one of the fixed virus strains. 
To confirm on  a  more quantitative basis cross-reactivity between  antigens recog- 
nized  by  hybridoma  antibody  194-2  (Table  VII)  serial  threefold  dilutions  of the 
antibody were mixed with 20-100 focus-forming units of strains 1, 3, 5, 6, and PV-11, 
respectively and  the mixtures added to monolayers of BHK-21  cells. The antibody 
titers determined by rapid fluorescent focus-inhibition technique  (13)  were the same 
against each of the five virus strains. 
Identification of the origin of street viruses (Table VIII) confirmed the validity of 
their classification on  the basis of antigenic properties of their glycoproteins. Thus, 
strains 5 and  7 represent two samples of rabies virus isolated from the same patient, 
and strains  1 and 8  are samples of rabies virus isolated from brains of the donor and 
the recipient, respectively, of a  corneal transplant (16). 
Fixed  Virus  Vaccine Strain  Does  Not  Give  Uniform  Protection  against  Street  Virus 
Variants.  Groups of mice were inoculated with a  vaccine produced from strain PV- 
11 and then challenged intracerebrally with dilutions of homologous virus or of street 
viruses 2, 5, 6, and 7, respectively. Only the latter street virus samples were available 
in large enough concentrations at an early passage level in mice to be used in serial 
dilutions for challenge of vaccinated mice. Fig. 3 shows that vaccination with PV- 11 
protected against challenge with homologous virus as well as with street viruses 2 and 
6. Conversely, challenge with street virus 7 and 5 resulted in 40 and 20-40% mortality, T.  J.  WIKTOR  AND  H.  KOPROWSKI  107 
TABLE  VII 
Analysis of Human Rabies Virus Isolates and Vaccine Strains with Selected  Anti- 
Glycoprotein Monoclonal Antibodies 
Hybrid- 
oma clone 
Results of neutralization test with human ra- 
bies virus isolates numbers 
Results of neutraliza- 
tion with vaccine 
strains 
4, 5,  7  1 and 8  2 and 6  CVS- 
(A)  (B)  (C)  3 (D)  PV-  11  DEV 
194-2  +  +  +  +  +  + 
248-2  +  +  +  +  +  + 
613-2  +  +  +  +  +  + 
101-1  +  +  +  +  0  0 
162-5  +  +  +  +  0  0 
110-3  0  +  +  +  +  + 
507-1  0  +  +  +  +  + 
5O9-6  0  +  +  +  +  + 
528-2  0  +  +  +  +  + 
231-22  0  0  +  +  +  + 
120-6  0  0  +  +  +  + 
176-2  0  0  +  +  0  + 
193-2  0  0  +  +  0  + 
503-1  +  0  0  +  0  0 
An  additional  10  antibodies did  not  react  with strains of groups A-D.  100  tissue 
culture-infective doses  of virus  mixed  with  1:5  dilution  of  respective hybridoma 
antibody were added to BHK-21 monolayers, and the number of loci of virus-infected 
cells was determined by  FA  staining. 0,  >50%  of cells showing fluorescence--no 
neutralization. +, no cells showing fluorescence--positive neutralization. 
respectively, of vaccinated mice, regardless of the challenge dose used. Sera drawn 
from vaccinated mice at the time of challenge neutralized the PV- 11  (vaccine) strain 
at a dilution of 1:7,200,  and the strain 7, which caused 40% mortality in vaccinated 
mice, at a  dilution of 1:2,400.  Mortality resulted from rabies infection as evidenced 
by the presence of rabies antigen in the brain (FA staining) and by recovery of rabies 
virus after intracerebral inoculation of brain homogenate of diseased mice into naive 
mice. 
Discussion 
As has been observed previously with influenza (17,  18)  and parainfluenza virus 
(J. w. Yewdell, Personal communication.), the present study shows that rabies virus 
variants can readily be selected in vitro from a  cloned parental virus seed (CVS-11) 
if the latter is grown in the presence of a concentration of monoclonal antibody able 
to neutralize at least 10  4.3-10  5 infectious units of parental CVS virions. Rabies variants 
selected in this way can be characterized, briefly, as follows: first, variants in single 
glycoprotein epitopes (viz., antigenic structure delineated by the combining site of an 
individual monoclonal hybridoma antibody) are present in cloned rabies virus seed at 
a frequency of 10  -4"a- 10  -5. Although final proof (comparison of amino acid sequences 
of parental and variant glycoprotein) is still lacking, the high frequency of occurrence 
of the variants suggests that they represent single point glycoprotein mutants of the 
parental CVS virus. Second, the antigenic change exhibited by these variants prevents 
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T^nLE  VIII 
Origin of Street Viruses Isolated  from Human Brains 
Street 
number  Group* 
Oklahoma, 1979, exposure unknown 
Maryland, 1976, infection by bat bite:]:  A 
The same as 5 
Oregon, 1978, exposure  unknown; donor of  corneal 
transplant for case 8 
Idaho, 1978; recipient of corneal transplant from  B 
case 1 
Texas, 1976, infection by dog bite in Mexico 
Texas, 1976, infection by dog bite in Mexico§  C 
Minnesota, 1974, infection by cat bite[I  D 
* See Table VII. 
J~ Patient received human rabies immune globulin (HRIG) and 21  doses of 
vaccine starting from day 2 after exposure. 
§ Patient received HRIG and vaccination after development of symptoms. 
[] Patient received 14 doses of vaccine  starting 3 wk after exposure. 
Note: all other cases were not treated. 
variants  but  does  not  affect  detectably  the  neutralizing  potency  of  many  other 
monoclonal antibodies or of antirabies antisera. Thus, the antigenic changes exhibited 
by  the  variants  represent  minor  modifications  of  the  overall  antigenicity  of  the 
parental glycoprotein. 
The above findings clearly demonstrate that rabies virus has a similar potential as 
influenza  to undergo  antigenic  variation under suitable experimental conditions  in 
vitro. However, unlike influenza, the existence of antigenic variants of rabies in nature 
has  only become fully apparent  when  monoclonal  antibodies  were  applied  in  the 
analysis of field strains isolated in different parts of the world (6).  The present study 
also shows that  the virus isolated  from seven fatal cases of human  rabies represent 
antigenic variants. It is noteworthy, that a  complete postexposure vaccination treat- 
ment had been given to case 5  (7)  (Table VIII) of these fatal rabies cases. Thus, the 
question  could  be  raised  whether  the  inability  of standard  fixed  virus  vaccine  to 
protect  rabies-infected  individuals  may be caused  by  antigenic  variation  of street 
virus. 
The epidemiologic and pathogenic significance of antigenic variation in rabies was 
assessed first  in  cross-protection experiments using the  variants isolated  under con- 
trolled conditions in vitro. It was found that mice immunized with one variant and 
showing the presence of high titer of cross-reacting antibodies in their sera could not 
withstand  challenge with another variant or with  the parental  virus. Only variants 
such  as  RV  101-1  and  RV  231-22  (Table  III)  which  could  be  paired  in  group  I 
showed reciprocal cross-protection in mice. 
It has been observed previously 09)  that serum with neutralizing titer of l:300-1: 
1,000  (2-6  IU)  antibody  protected  all  mice infected  intracerebrally  with  the  CVS 
strain.  The  discrepancy  between  those  results  and  the  present  finding  cannot  be 
satisfactorily explained unless we postulate that  only humoral antibodies of certain 
defined anti-glycoprotein specificities protect in vivo or alternately, that factors other 
than humoral  immunity play a  decisive role in  resistence of animals against  intra- 
cerebral challenge with rabies. T.  J.  WIKTOR  AND  H.  KOPROWSKI  109 
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CHALLENGE  VIRUS  DILUTIONS  (LOG  IO) 
Fro.  3.  Protection by vaccine prepared from PV-11 virus against challenge with homologous virus 
and against challenge with four street strains of rabies virus. Percent mortality after challenge with 
indicated virus dilutions.  O, vaccinated mice; 0, unvaccinated controls. 
Failure of cross-protection between variants, coupled with the high frequency of 
variants among the street strains of rabies isolated from fatal human cases, pose the 
question  of whether  mice  vaccinated  with  standard  vaccine prepared  from  fixed 
viruses such as PV-11 or CVS-DEV would be protected against challenge with street 
virus representing different variant groups. 
As was shown in Fig.  3, vaccination of mice with vaccine produced from PV-11 
strain protected mice completely against lethal challenge with either homologous or 
the 2 or 6 street virus variants of group C, but only partially protected mice challenged 
with street virus 5 and  7 of group A. The latter results are rather hard to interpret 
because ~40% of vaccinated animals died after challenge with either street virus 5 or 
7 regardless of whether they were challenged with undiluted virus or with  10  -1,  10  -2, 
or 10  -3 (in the case of virus 7 challenge) dilutions of the virus suspension. This could 
hardly be explained by the existence of a  mixture of two rabies populations in the 
challenge inoculum.  It  is  possible that  individual  responses to vaccination of mice 
may have differed and that  if inbred strains of mice instead of the ICR stock were 
used  in  the  same  type  of experiment,  the  challenge  results  would  become  more 
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The fact that  vaccine prepared from variants obtained by single point  mutation 
cannot protect mice against challenge with either parental or another variant virus 
(Figs.  1 and  2),  and  that  relatively large  numbers of street  virus  variants  exist  in 
different parts of the world (6) and within a group of seven strains of viruses isolated 
from fatal human cases of rabies in the United States and Mexico (Table VIII) poses 
a question of whether the method of selection and of testing rabies strains for vaccine 
production for preventive and postexposure treatment of animals and man is correct. 
Rabies  vaccines are produced in  many countries.  No more than  three strains of 
fixed virus, two of which are derived from the original Pasteur strain, are used for 
production of vaccines throughout the world (20)  regardless of whether the vaccines 
are made in animal brain, duck embryo, or tissue culture. 
Evaluation of the antigenic potency of the rabies  vaccine is also a  standardized 
procedure (21) adopted by most countries of the world. Mice are immunized with the 
vaccine and then challenged with a strain of fixed virus, usually the CVS, distributed 
from one stock by an international organization (20).  CVS is a  fixed strain of rabies 
also derived from Pasteur's strain;  thus antigenicity of one derivative of the Pasteur 
strain is checked by challenge of mice with another derivative of Pasteur's strain, and 
this vaccine is used for protection of men and  animals against  street viruses which 
may, in different areas of the world, represent variants expressing antigens which do 
not cross-react with either of the strains of the fixed viruses involved in the vaccine 
evaluation  procedure.  Only  once  in  the  modern  history  of rabies  research  has  a 
potency test been developed for a live virus animal vaccine (22) in which vaccinated 
animals were challenged with street virus instead of fixed virus. In spite of its successful 
applications to the evaluation of vaccines (23), this type of potency test  had  to be 
abandoned because of opposition by vaccine manufacturers and licensing authorities 
to its use. 
In  the light  of results presented in  this  paper,  however, the currently employed 
vaccine potency test should be immediately changed by modifying it through chal- 
lenge of vaccinated animals  with  a  street  virus  prevalent  in  a  given  geographical 
region. If vaccinated mice succumb to challenge with the virus, the existing vaccine 
should be replaced by one which uses fixed virus-expressing antigen(s) which evoke in 
the vaccinated individual an immune response capable of protecting it from exposure 
to street viruses in that  particular region.  Selection of fixed viruses tailored to the 
local needs may not be a simple matter, but then, the number of street virus variants 
in any given area may not be as great as feared. For instance, the two Mexican isolates 
reported in this paper, the two isolates from foxes in France and the Federal Republic 
of Germany (6), and two human isolates from U. S. S. R. (6) could be paired, on the 
basis of their reactivity with monoclonal antibodies, as apparently identical variants 
of rabies representing a certain geographical region. Moreover, further studies along 
the lines presented in this paper may lead to the development of methods permitting 
relatively rapid  identification of antigenic  sites  of fixed virus strains  which  would 
engender the broadest possible protective response to challenge with a large number 
of variants of street virus. 
Summary 
Antigenic variants of CVS- 11 strain of rabies virus were selected after treatment of 
virus  populations  with  monoclonal  antibodies  directed  against  the  glycoprotein T. J. WIKTOR AND H.  KOPROWSKI  111 
antigen of the virus. These variants resisted neutralization by the hybridoma antibody 
used for their selection. Two independently mutating antigenic sites could be distin- 
guished when five variants were tested with nine hybridoma antibodies. The frequency 
of single epitope variants in a cloned rabies virus seed was ~ 1:10,000.  Animals were 
not or only partially protected when challenged with the parent virus or with another 
variant, but were fully protected against challenge with the virus used for immuni- 
zation.  Variants were also detected  among seven street  viruses obtained  from fatal 
cases  of  human  rabies.  Animals  immunized  with  standard  rabies  vaccine  were 
protected against challenge with some but not all street rabies variants. A comparative 
antigenic analysis between vaccine strain and challenge virus by means of monoclonal 
antiglycoprotein antibodies showed  a  slightly closer degree of antigenic  relatedness 
between vaccine and challenge strain in the combinations where vaccination resulted 
in protection. It remains unknown, however, whether these apparently minor antigenic 
differences in  the  glycoproteins account  for the  varying degrees of protection.  The 
results  of this  study  clearly  indicate  that  the  selection  of vaccine  strains  and  the 
methods used to evaluate the potency of rabies vaccines need tobe revised. 
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